Cerus (NASDAQ:CERS) Issues Earnings Results

Cerus (NASDAQ:CERS) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.00 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.02, FiscalAI reports. Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%.The company had revenue of $60.24 million during the quarter, compared to analysts’ expectations of $55.12 million. Cerus updated its FY 2025 guidance to EPS.

Cerus Stock Performance

Shares of CERS stock traded down $0.04 on Thursday, hitting $1.41. The company had a trading volume of 982,070 shares, compared to its average volume of 1,318,525. The firm has a market cap of $270.30 million, a P/E ratio of -14.10 and a beta of 1.67. The company has a 50-day moving average price of $1.46 and a 200-day moving average price of $1.38. The company has a quick ratio of 1.35, a current ratio of 2.00 and a debt-to-equity ratio of 1.01. Cerus has a twelve month low of $1.12 and a twelve month high of $2.24.

Hedge Funds Weigh In On Cerus

Several institutional investors and hedge funds have recently modified their holdings of CERS. Dynamic Technology Lab Private Ltd purchased a new position in shares of Cerus in the 1st quarter valued at about $32,000. HUB Investment Partners LLC purchased a new position in shares of Cerus in the 2nd quarter valued at about $42,000. Captrust Financial Advisors increased its stake in shares of Cerus by 89.7% in the 2nd quarter. Captrust Financial Advisors now owns 31,109 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 14,709 shares in the last quarter. Brevan Howard Capital Management LP increased its stake in shares of Cerus by 228.1% in the 2nd quarter. Brevan Howard Capital Management LP now owns 47,823 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 33,249 shares in the last quarter. Finally, Cerity Partners LLC increased its stake in shares of Cerus by 46.3% in the 2nd quarter. Cerity Partners LLC now owns 69,486 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 21,996 shares in the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cerus in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Cerus presently has an average rating of “Hold” and an average target price of $4.00.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.